Alexandria Real Estate Equities ARE

NYSE ARE

$49.56 -0.78 (-1.55%)

As of: Sep 10, 2026 · 3:59 PM EDT

Key Stats

Market Cap8.47 Bn

P/E-8.21

P/S2.98

Div. Yield0.09

Total Debt (Qtr)12.81 Bn

Revenue Growth (1y) (Qtr)-13.03

Add ratio to table…

About

Alexandria Real Estate Equities, Inc. is a real estate investment trust that operates as a best-in-class life science REIT focused on owning, operating, and developing collaborative Megacampus™ ecosystems. The company specializes in Class A/A+ properties located in premier life science innovation clusters across North America. Its core business involves creating high-quality laboratory and research facilities designed to support scientific innovation and tenant…

Alexandria Real Estate Equities, Inc. generates revenue primarily through leasing its portfolio of laboratory and research facilities to tenants in the life science sector. Rental income is derived from long-term leases with pharmaceutical, biotechnology, medical device, and technology companies, as well as academic and government research institutions. The company also earns revenue through strategic capital investments in transformative life science companies via its venture capital platform.

The company operates through the following segments:

Greater Boston: This segment focuses on the ownership, operation, and development of life science properties in the Greater Boston area, a major hub for biotechnology and pharmaceutical research. Properties in this segment are designed to support innovation through collaborative Megacampus™ ecosystems that integrate laboratory, office, and amenity spaces. The segment benefits from proximity to leading academic institutions and medical research centers, enhancing its ability to attract and retain high-quality tenants.
San Francisco Bay Area: This segment manages properties in one of the most dynamic life science innovation clusters, encompassing areas such as San Francisco, San Jose, and surrounding regions. The segment emphasizes the development of flexible, reusable laboratory spaces that cater to a diverse mix of biotech, digital health, and advanced technology firms. Its strategy includes leveraging proximity to top-tier universities and research hospitals to foster tenant growth and collaboration.
San Diego: This segment operates in a concentrated life science market known for strong presence in genomics, immunology, and pharmaceutical research. Properties in this segment are developed to meet the specialized needs of life science tenants through state-of-the-art laboratory infrastructure and campus-style environments. The segment prioritizes access to transit and curated amenities to support talent attraction and retention for its tenants.
Seattle: This segment serves the growing life science and technology corridor in the Pacific Northwest, focusing on properties that support biotechnology, global health, and advanced computing research. The segment’s developments are designed with sustainability and scalability in mind, offering tenants space that can evolve with their research needs. Proximity to major research institutions and innovation hubs strengthens its competitive positioning in the region.
Maryland: This segment centers on properties located along the I-270 technology corridor and other key life science submarkets in the state. The segment emphasizes integration with federal research agencies and private-sector biotech firms, supporting missions in health defense and therapeutic innovation. Its Megacampus™ approach enables tenants to expand operations within a cohesive, amenity-rich environment.
Research Triangle: This segment operates in the Raleigh-Durham-Chapel Hill area, a nationally recognized hub for life sciences and technology innovation. Properties in this segment are tailored to support the research and development needs of pharmaceutical, agtech, and contract research organizations. The segment benefits from strong ties to major universities and a deep talent pool in the life sciences.
New York City: This segment focuses on high-density urban life science properties in one of the nation’s largest centers for biomedical research and healthcare innovation. Developments in this segment prioritize access to major medical centers, academic institutions, and transit infrastructure to support tenant operations. The segment addresses the unique challenges of urban development by delivering high-quality, efficient laboratory spaces in constrained environments.
Texas: This segment encompasses properties in emerging life science markets such as Austin, Dallas, and Houston, where the company is expanding its presence through strategic acquisitions and developments. The segment targets growth in energy-adjacent biotech, medical device, and digital health sectors. Its strategy includes building collaborative campuses that attract both established firms and early-stage innovators seeking access to capital and talent.

Alexandria Real Estate Equities, Inc. holds a leading position in the life science real estate industry as the pioneering and longest-tenured owner, operator, and developer of Megacampus™ ecosystems. The company differentiates itself through its deep integration with scientific innovation clusters and its focus on creating collaborative, amenity-rich environments that enhance tenant productivity and retention. Competitors include other office and laboratory REITs, but Alexandria maintains an edge through its specialized focus, long-term tenant relationships, and proven track record in developing high-demand life science infrastructure.

The company serves a diverse tenant base within the life science industry, including multinational pharmaceutical corporations, public and private biotechnology firms, medical device and diagnostics companies, digital health and agtech enterprises, academic and medical research institutions, U. S. government research agencies, non-profit organizations, and venture capital firms. Notable tenants include major pharmaceutical companies, leading biotech innovators, and prominent research institutions, though specific names are not detailed in this excerpt.

Investment Thesis

▲ Bull case

Alexandria Real Estate Equities, Inc. (ARE) maintains a deeply entrenched competitive moat through its Megacampus platform, which generated 78% of first-quarter 2026 annualized rental revenue and demonstrates persistent demand resilience despite macro headwinds. The company’s ability to capture twice its market share in leasing volume across its top three markets—Greater Boston (153% of share), San Francisco Bay (253% of share), and San Diego (208% of share)—underscores unmatched tenant preference for its integrated ecosystems, where location, operational excellence, and brand trust drive occupancy outperformance in the mid- to high-80% range versus market averages in the mid- to high-70s. This structural advantage is reinforced by a tenant base where 55% of annualized rental revenue comes from investment-grade or large-cap public companies with an average weighted-average lease term of nearly 10 years for the top 20 tenants, providing predictable cash flows insulated from short-term biotech volatility. Furthermore, the company’s disciplined capital allocation—evidenced by $7.4 million in quarterly G&A savings versus 2024 averages and a trajectory toward $76 million in cumulative savings over 2025–2026—directly enhances NOI conversion, with adjusted EBITDA margins holding at 66% in Q1 2026 despite occupancy pressure. These fundamentals position ARE to benefit disproportionately from any stabilization in life science R&D spending, particularly as NIH funding uncertainty eases following the court victory over the 15% indirect cost reimbursement limitation, which management noted will be “very well received and implemented over the coming quarters and years.” The mega campuses’ scale and flexibility also enable capture of emerging demand from advanced technology tenants—such as Amazon’s research arm and Leidos’ screening operations—expanding the addressable market beyond traditional life science while preserving core lab functionality. Finally, the substantial progress on the $2.9 billion disposition pipeline, with 80% of the midpoint already pending or identified and a weighted average completion date now guided to August 2026 (a one-month delay reflecting prudent execution rather than weakness), will unlock liquidity to strengthen the balance sheet further, reduce net leverage from the current quarterly annualized 6.8x toward the guided 5.6x–6.2x range by year-end, and recycle capital into higher-yielding opportunities without forcing distressed sales, all while maintaining the longest average debt maturity among S&P 500 REITs at 10 years.

Alexandria Real Estate Equities, Inc. (ARE) maintains a deeply entrenched competitive moat through its Megacampus platform, which generated 78% of first-quarter 2026 annualized rental revenue and demonstrates persistent demand resilience despite macro headwinds. The company’s ability to capture twice its market share in leasing volume across its top three markets—Greater Boston (153% of share), San Francisco Bay (253% of share), and San Diego (208% of share)—underscores unmatched tenant preference for its integrated ecosystems, where location, operational excellence, and brand trust drive occupancy outperformance in the mid- to high-80% range versus market averages in the mid- to high-70s. This structural advantage is reinforced by a tenant base where 55% of annualized rental revenue comes from investment-grade or large-cap public companies with an average weighted-average lease term of nearly 10 years for the top 20 tenants, providing predictable cash flows insulated from short-term biotech volatility. Furthermore, the company’s disciplined capital allocation—evidenced by $7.4 million in quarterly G&A savings versus 2024 averages and a trajectory toward $76 million in cumulative savings over 2025–2026—directly enhances NOI conversion, with adjusted EBITDA margins holding at 66% in Q1 2026 despite occupancy pressure. These fundamentals position ARE to benefit disproportionately from any stabilization in life science R&D spending, particularly as NIH funding uncertainty eases following the court victory over the 15% indirect cost reimbursement limitation, which management noted will be “very well received and implemented over the coming quarters and years.” The mega campuses’ scale and flexibility also enable capture of emerging demand from advanced technology tenants—such as Amazon’s research arm and Leidos’ screening operations—expanding the addressable market beyond traditional life science while preserving core lab functionality. Finally, the substantial progress on the $2.9 billion disposition pipeline, with 80% of the midpoint already pending or identified and a weighted average completion date now guided to August 2026 (a one-month delay reflecting prudent execution rather than weakness), will unlock liquidity to strengthen the balance sheet further, reduce net leverage from the current quarterly annualized 6.8x toward the guided 5.6x–6.2x range by year-end, and recycle capital into higher-yielding opportunities without forcing distressed sales, all while maintaining the longest average debt maturity among S&P 500 REITs at 10 years.

▼ Bear case

Alexandria Real Estate Equities, Inc. (ARE) faces mounting structural headwinds that threaten to erode its occupancy and NOI recovery trajectory, particularly as public biotech leasing remained at zero in Q1 2026—a segment representing 24% of annualized rental revenue—signaling a persistent funding gap for preclinical and clinical-stage companies unable to access public markets without data or milestones. This dynamic is exacerbated by ongoing FDA leadership instability and NIH budget pressures, which management acknowledged create a “shock effect” on investor confidence and capital allocation, directly impacting tenants’ ability to commit to long-term space needs. The company’s guidance reductions—cutting year-end 2026 occupancy from 88.5% to 87% and same-property NOI from down 8.5% to down 9.5%—reflect a strategic pivot away from selling vacant assets due to stronger-than-expected leasing interest on those properties, meaning ARE is now holding more low-occupancy space longer than planned, which will continue to drag on NOI conversion and same-store performance through at least Q3 2026 when the 1.1 million square feet of leased vacant space is expected to deliver. Furthermore, the $97 million in annualized revenue tied to 1.5 million square feet of 2027 lease expirations introduces significant forward occupancy risk, with management admitting they cannot yet predict retention rates and noting that 35%–36% of that space has only early negotiations—far from committed leases—suggesting a high likelihood of prolonged downtime that could replicate or exceed 2026’s occupancy pressures. Concurrently, the company’s reliance on dispositions for deleveraging is increasingly uncertain, as the transaction market’s strength remains unproven at scale despite management’s confidence; the Q1 2026 quarter was described as “relatively quiet” for dispositions, and the shift toward joint ventures for core assets introduces execution complexity and potential dilution of control over prime Megacampus locations. Finally, ARE’s balance sheet, while liquid with $4.2 billion in available funds, shows leverage rising to 6.8x on a quarterly annualized basis in Q1 2026, and the guided 5.6x–6.2x year-end net debt-to-EBITDA range depends entirely on successful disposition execution—any delay or pricing shortfall in the $2.9 billion program would leave the company overleveraged relative to peers, constraining financial flexibility precisely when tenant demand remains volatile and capital expenditures on evaluation-stage projects (like the $1.3 billion in assets with 2027 milestones) could require sudden funding if advanced technology leasing fails to materialize as hoped.

Alexandria Real Estate Equities, Inc. (ARE) faces mounting structural headwinds that threaten to erode its occupancy and NOI recovery trajectory, particularly as public biotech leasing remained at zero in Q1 2026—a segment representing 24% of annualized rental revenue—signaling a persistent funding gap for preclinical and clinical-stage companies unable to access public markets without data or milestones. This dynamic is exacerbated by ongoing FDA leadership instability and NIH budget pressures, which management acknowledged create a “shock effect” on investor confidence and capital allocation, directly impacting tenants’ ability to commit to long-term space needs. The company’s guidance reductions—cutting year-end 2026 occupancy from 88.5% to 87% and same-property NOI from down 8.5% to down 9.5%—reflect a strategic pivot away from selling vacant assets due to stronger-than-expected leasing interest on those properties, meaning ARE is now holding more low-occupancy space longer than planned, which will continue to drag on NOI conversion and same-store performance through at least Q3 2026 when the 1.1 million square feet of leased vacant space is expected to deliver. Furthermore, the $97 million in annualized revenue tied to 1.5 million square feet of 2027 lease expirations introduces significant forward occupancy risk, with management admitting they cannot yet predict retention rates and noting that 35%–36% of that space has only early negotiations—far from committed leases—suggesting a high likelihood of prolonged downtime that could replicate or exceed 2026’s occupancy pressures. Concurrently, the company’s reliance on dispositions for deleveraging is increasingly uncertain, as the transaction market’s strength remains unproven at scale despite management’s confidence; the Q1 2026 quarter was described as “relatively quiet” for dispositions, and the shift toward joint ventures for core assets introduces execution complexity and potential dilution of control over prime Megacampus locations. Finally, ARE’s balance sheet, while liquid with $4.2 billion in available funds, shows leverage rising to 6.8x on a quarterly annualized basis in Q1 2026, and the guided 5.6x–6.2x year-end net debt-to-EBITDA range depends entirely on successful disposition execution—any delay or pricing shortfall in the $2.9 billion program would leave the company overleveraged relative to peers, constraining financial flexibility precisely when tenant demand remains volatile and capital expenditures on evaluation-stage projects (like the $1.3 billion in assets with 2027 milestones) could require sudden funding if advanced technology leasing fails to materialize as hoped.

Segments Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Office REITs

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	BPYPM	Brookfield Property Partners L.P.	primary	15.45 Bn	-60.58	2.16	28.14 Bn
2	ARE	Alexandria Real Estate Equities, Inc.	primary	8.47 Bn	-8.21	2.98	12.81 Bn
3	CUZ	Cousins Properties Inc	primary	4.59 Bn	-9.38	4.44	3.73 Bn
4	KRC	Kilroy Realty Corp	primary	4.05 Bn	15.75	3.63	3.95 Bn
5	CDP	Copt Defense Properties	primary	4.00 Bn	24.39	5.11	2.59 Bn
6	SLG	Sl Green Realty Corp	primary	3.65 Bn	-19.13	3.51	2.23 Bn
7	HIW	Highwoods Properties, Inc.	primary	3.36 Bn	21.90	4.08	3.52 Bn
8	DEI	Douglas Emmett Inc	primary	1.79 Bn	-4.63	1.77	5.72 Bn

Alexandria Real Estate Equities ARE

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password